On the afternoon of May 23, Shenzhen Neptunus Bioengineering Co.Ltd(000078) ( Shenzhen Neptunus Bioengineering Co.Ltd(000078) . SZ) held the 2021 annual general meeting of shareholders in the conference room of Haiwang Galaxy Science and technology building in Nanshan District, Shenzhen. At the meeting, various proposals such as the work report of the board of directors in 2021 were considered and adopted. In terms of the company, president Zhang Feng, Secretary of the board of directors Shen Dakai and other management attended the meeting.
Recently, the news that “scientists found that covid-19 treatment new drug stephanine has been patented” has been widely spread, and stephanine related concept stocks have been speculation in the market. Shenzhen Neptunus Bioengineering Co.Ltd(000078) was also included in the concept stock of stephanine because it has an invention patent for stephanine sustained-release preparation.
At the meeting, in the investor exchange link, Zhang Feng said in response to the reporter’s question of the daily economic news that stephanine is an old drug. The company only has the patent right of the invention patent of stephanine sustained-release preparation. When stephanine can be truly and comprehensively applied to covid-19 treatment in the future, further scientific experiments and demonstration are needed.
epidemic superimposed policy impact, and the revenue and profit in the first quarter of this year decreased
In 2021, Shenzhen Neptunus Bioengineering Co.Ltd(000078) achieved a revenue of 41.054 billion yuan, a year-on-year increase of 2.58%, and the net profit attributable to the parent company was 93.3 million yuan, turning losses into profits year-on-year, and -289 million yuan in the same period of last year. Among them, the company’s pharmaceutical commercial circulation business revenue was 30.426 billion yuan, a year-on-year decrease of 2.51%, accounting for 74.11% of the revenue, contributing to most of the company’s revenue.
In the first quarter of this year, Shenzhen Neptunus Bioengineering Co.Ltd(000078) revenue was 9.202 billion yuan, a year-on-year decrease of 9.20%, and the net profit attributable to the parent company was 70.93 million yuan, a year-on-year decrease of 22.48%. In the first quarterly report, the company said that the decline in revenue was mainly due to the impact of the epidemic on the progress of the company’s product delivery. So, in the current situation of multiple outbreaks across the country, how much impact does the company expect the epidemic to have on the annual performancep align=”center” style=”text-align:center;”> Photo source: screenshot of the first quarterly report
In the investor exchange session, Shen Dakai said in response to a reporter’s question from the daily economic news that the epidemic has been affecting the development of the company’s business. It is expected to have a certain impact in April, but the company’s plan is still to maintain steady growth in annual performance. “Not only our enterprises, but also the whole pharmaceutical circulation industry has been greatly affected by the epidemic.” Shen Dakai said. Zhang Feng said that the decline in the performance of the company’s pharmaceutical circulation business was not only affected by the epidemic, but also affected by a series of policy factors, including centralized procurement, and the whole profit space was sharply compressed.
In March 2021, Shenzhen Neptunus Bioengineering Co.Ltd(000078) received the reply on approving Shenzhen Neptunus Bioengineering Co.Ltd(000078) non-public development of shares issued by the CSRC. The CSRC approved the company’s non-public offering of no more than 651 million shares, and the total amount of funds raised this time was no more than 2.5 billion yuan. However, in March this year, the company announced that after obtaining the approval, the company has been actively promoting the non-public offering of shares. However, due to changes in the capital market environment, issuance timing and other reasons, the company failed to implement the non-public offering of shares within the validity period of the approval, and the approval expires automatically.
Why did the company fail to implement the fixed increase fund-raising? Zhang Feng said that the company’s announcement has been explained, and the announcement shall prevail.
talk about stephanine: it can not be promoted as covid-19 drug
In March this year, Shenzhen Neptunus Bioengineering Co.Ltd(000078) announcement disclosed that the company plans to plan major asset restructuring and mixed ownership reform. The company said at that time that it had recently received a notice from Shenzhen Haiwang Group Co., Ltd., the controlling shareholder of the company, and was currently planning Shenzhen Neptunus Bioengineering Co.Ltd(000078) mixed ownership reform, which would introduce strategic investors. The matter may involve the change of the actual controller of the companyp align=”center” style=”text-align:center;”> Source: screenshot of announcement
At the meeting, when the reporter asked about the above-mentioned major asset restructuring, Zhang Feng responded that the matter was still under preliminary investigation and was not convenient for disclosure for the time being.
The reporter of the daily economic news noted that as of May 13, Shenzhen Neptunus Bioengineering Co.Ltd(000078) accumulated guarantee balance was 5.657 billion yuan, accounting for 77.41% of the company’s net assets in the audited consolidated statements in 2021. Will such a high guaranteed balance be at risk? In this regard, Zhang Feng said that the vast majority of these guarantees are guarantees within the system of listed companies, which are directly related to the business. The company has been strengthening the internal management of its subsidiaries in recent years, and there will be no special risk in the guarantee.
Recently, the news that “scientists have found and patented covid-19 as a new therapeutic drug” has been widely spread. According to a report in science and technology daily, the covid-19 new therapeutic drug discovered by Chinese scientists has been authorized by the national invention patent. The patent specification shows that 10um (micromol / L) stephanine inhibits coronavirus replication by 15393 times. Since then, the concept stocks related to stephanine have been stir fried in the market. Due to the invention patent of stephanine sustained-release preparation, Shenzhen Neptunus Bioengineering Co.Ltd(000078) has also been included in the concept stocks of stephanine, and the company’s share price has ushered in a wave of rising market recently.
At the meeting, Zhang Feng said: “stephanine is an old medicine, and the company only has the patent right of the invention patent of stephanine sustained-release preparation. When stephanine can be truly and comprehensively applied to covid-19 treatment in the future, further scientific experiments and demonstration are needed, and there are still many unknown factors.”
